BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 25617950)

  • 1. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
    Kim JE; Kim SH; Lee SJ; Rhim H
    AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings.
    Kim SH; Lee WJ; Lim HK; Park CK
    Korean J Radiol; 2009; 10(2):112-20. PubMed ID: 19270856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
    Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
    Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker.
    Choi JW; Lee JM; Kim SJ; Yoon JH; Baek JH; Han JK; Choi BI
    Radiology; 2013 Jun; 267(3):776-86. PubMed ID: 23401584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small hepatocellular carcinomas in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging.
    Hayashida M; Ito K; Fujita T; Shimizu A; Sasaki K; Tanabe M; Matsunaga N
    Magn Reson Imaging; 2008 Jan; 26(1):65-71. PubMed ID: 17566685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images.
    Kwon HJ; Byun JH; Kim JY; Hong GS; Won HJ; Shin YM; Kim PN
    Abdom Imaging; 2015 Jan; 40(1):64-75. PubMed ID: 24997560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.
    Kim YK; Lee WJ; Park MJ; Kim SH; Rhim H; Choi D
    Radiology; 2012 Oct; 265(1):104-14. PubMed ID: 22891358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.
    Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J
    Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.